Fox Run Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Fox Run Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,545	Closed	-$198K	–	928
2018 Q2	$198K	Buy	+12,545	New	+$191K	0.06%	584
2017 Q3	–	Sell	-35,100	Closed	-$402K	–	966
2017 Q2	$402K	Buy	+35,100	New	+$649K	0.14%	308
2017 Q1	–	Sell	-17,500	Closed	-$364K	–	825
2016 Q4	$364K	Buy	+17,500	New	+$455K	0.19%	231

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fox Run Management's ALDR Position: Q3 2018 in Review

Fox Run Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 12,545 shares — an estimated $198K sold.

Fox Run Management first reported a position in ALDR in Q4 2016 and held it in 3 quarters. The position peaked at $402K in Q2 2017. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

Fox Run Management reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
Fox Run Management sold 12,545 Alder Biopharmaceuticals shares in Q3 2018, an estimated $198K.
Fox Run Management first reported a position in Alder Biopharmaceuticals in Q4 2016 and held it in 3 quarters.
Fox Run Management's Alder Biopharmaceuticals position peaked at $402K in Q2 2017.
127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on Fox Run Management's 13F filing for Q3 2018, filed 5 Oct 2018.